Search Results - "Bianchi, GV"

Abstract P6-17-05: Independent validation of a combined biomarker based on the PAM50 HER2-enriched subtype and ERBB2 mRNA levels following HER2 blockade without chemotherapy in the PerELISA phase II trial by Prat, A, Griguolo, G, Dieci, MV, Bisagni, G, Frassoldati, A, Bianchi, GV, Pascual, T, Pare, L, Galvan, P, Urso, L, Conte, P, Guarneri, V

“…Abstract Background: A combined biomarker based on HER2-enriched subtype (HER2-E) and ERBB2 mRNA predicts response and survival in HER2+ breast cancer…”
Get full text

Abstract P2-02-19: Circulating tumor DNA detection anticipates disease recurrence in early stage breast cancer: A pilot study generating an observational confirmatory trial by Daidone, MG, Di Cosimo, S, Veneroni, S, Cascone, F, De Cecco, L, Dugo, M, Folli, S, Bianchi, GV, Tamborini, E, Busico, A, Appierto, V

“…Abstract Sensitive tumor biomarkers able to monitor disease progression would contribute to post-surgical treatment decision making in early breast cancer. We…”
Get full text

Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC) by Campone, M, Sachdev, J, Bianchi, GV, Beck, JT, Martínez-Jáñez, N, Cortes, J, Schmidt, M, Zamagni, C, Chen, P, Miller, J, Fandi, A, Gianni, L

“…Abstract Background: Most patients diagnosed with breast cancer have ER+ tumors. Treatment of ER+ MBC typically involves endocrine therapy, including aromatase…”
Get full text

Abstract P1-09-04: Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies by Bianchini, G, Pienkowski, T, Im, Y-H, Bianchi, GV, Tseng, L-M, Liu, M-C, Lluch, A, de la Haba-Rodríguez, J, Semiglazov, V, Oh, D-Y, Poirier, B, Pedrini, JL, Valagussa, P, Gianni, L

“…Abstract Background: Patients (pts) with residual disease (RD) after neoadjuvant therapy are at higher risk of relapse. We investigated whether biomarkers…”
Get full text

Characterizing Different Multidisciplinary Team Models Implemented Within One Comprehensive Cancer Center by Alfieri, Sara, Brunelli, Cinzia, Borreani, Claudia, Capri, Giuseppe, Angi, Martina, Bianchi, Giulia V, Lo Dico, Silvia, Spada, Pierangelo, Fusetti, Viviana, Zecca, Ernesto, Caraceni, Augusto

“…The multidisciplinary approach is considered "best practice" in oncology. Multidisciplinary Teamwork (MDTW) can be broadly classified into Multidisciplinary…”
Get full text

Abstract P4-01-10: Preoperative [18F]-fluoro-3’-deoxy-3’-L-thymidine positron emission tomography computed tomography (FLT-PET/CT) to predict early response to neoadjuvant chemotherapy in patients with primary breast cancer: Exploratory experience by Mariani, G, Agresti, R, Ricchini, F, Bianchi, GV, Capri, G, Alessi, A, Padovano, B, De Braud, F, Crippa, F

“…Abstract Background Neoadjuvant chemotherapy (NAC) plays a crucial role in the treatment of breast cancer (BC) with not only the possibility to increase the…”
Get full text

Abstract P3-12-13: First analysis of ASTER study AT for 3 cycles followed by CMF for 3 cycles as neo or adjuvant chemotherapy in early stage breast cancer. A single institution experience by Mariani, G, Galli, G, Mariani, P, Bianchi, GV, Capri, G, Cresta, S, Damian, S, De Benedictis, E, Valagussa, P, Magazzu', D, De Braud, FG, Moliterni, A

“…Abstract Background: The ECTO study demonstrated the efficacy of concurrent doxorubicin and paclitaxel (AT) for 4 cycles followed by cyclophosphamyde/…”
Get full text

P1-12-02: Patient-Reported Outcomes (PROs) from a Randomized Phase II Study (TDM4450g/BO21976) of Trastuzumab Emtansine (T-DM1) vs Trastuzumab Plus Docetaxel (HT) in Previously Untreated HER2−Positive Metastatic Breast Cancer (MBC) by Bianchi, GV, Kocsis, J, Dirix, L, Torigoe, Y, Lalla, D, Tong, YB, Guardino, AE, Hurvitz, SA

“…Abstract Background: T-DM1 is an antibody-drug conjugate in development for HER2−positive cancer. As a single-agent, it has demonstrated promising efficacy and…”
Get full text